Search results
Results from the WOW.Com Content Network
An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...
Theophylline's first clinical use came in 1902 as a diuretic. [35] It took an additional 20 years until it was first reported as an asthma treatment. [ 36 ] The drug was prescribed in a syrup up to the 1970s as Theostat 20 and Theostat 80, and by the early 1980s in a tablet form called Quibron.
Treat an asthma attack by visiting the hospital. Every year, more than 1.6 million Americans wind up in the emergency room because of an asthma attack, according to the CDC.If your attack is so ...
A diuretic (/ ˌ d aɪ j ʊ ˈ r ɛ t ɪ k /) is any substance that promotes diuresis, the increased production of urine. This includes forced diuresis. A diuretic tablet is sometimes colloquially called a water tablet. There are several categories of diuretics. All diuretics increase the excretion of water from the body, through the kidneys ...
They are both inhaled and given by aerosol delivery devices. [5] [6] Long-lasting β 2-agonists are often given in a combination with corticosteroids to treat asthma. Short-acting β 2-agonists are used to treat exercise-induced asthma, [7] and for asthma patients to get a quick relief of symptoms. They are taken 10–15 minutes before exercise.
The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.
Drugs with muscarinic antagonist activity are widely used in medicine, in the treatment of low heart rate, overactive bladder, respiratory problems such as asthma and chronic obstructive pulmonary disease (COPD), and neurological problems such as Parkinson's disease and Alzheimer's disease.
After Belsomra hit the market, Consumer Reports asked Schwartz to create a label for it. Her version presents the data on the drug in an even-handed way, noting that its ability to aid sleep is “modest” at the highest approved doses. “Short track record means that new, unexpected side effects are possible,” it explains.